(AGENPARL) - Roma, 15 Marzo 2023(AGENPARL) – SILVER SPRING mer 15 marzo 2023
Submit Comments by 06/14/2023
Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document’s docket number: FDA-2023-D-0608
- Docket Number:
- FDA-2023-D-0608
- Issued by:
-
Guidance Issuing Office
Center for Drug Evaluation and Research
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Development of Local Anesthetic Drug Products With Prolonged Duration of Effect.” The draft guidance reflects the Agency’s current recommendations regarding drug development and trial design issues relevant to the study of local anesthetic drug products with prolonged duration of effect for which submission of a new drug application (NDA) is planned. The recommendations in the guidance are intended to assist developers in generating the data necessary to support different indications and labeling claims for these drugs.
Fonte/Source: http://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-local-anesthetic-drug-products-prolonged-duration-effect
